Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics

Journal of Clinical Pharmacology

Volumn 39, Issue 11, 1999, Pages 1189-1194

  Harris, R Z ^a   Ingles, A M L ^a   Miller, A K ^a   Thompson, K A ^a   Finnerty, D ^a   Patterson, S ^a   Jorkasky, D K ^a   Freed, M I ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; ERYTHROMYCIN; INDINAVIR; ITRACONAZOLE; NIFEDIPINE; RIFAMPICIN; ROSIGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN;

ADOLESCENT; ADULT; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; NIFEDIPINE; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 0033306883     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. The synthesis of BRL 49653 - A novel and potent anti-hyperglycaemic agent
2. Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats
3. Efficacy and metabolic effects of metformin and trogli-tazone in type II diabetes mellitus
4. Rosiglitazone (BRL 49653) monotherapy has significant glu-cose lowering effect in type 2 diabetic patients
5. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
6. Role of insulin resistance in human disease (syndrome X): An expanded definition
7. Ef-fect of troglitazone on terfenadine pharmacokinetics when dosed 4-hours apart
8. Effect of troglitazone on terfenadine pharmacokinetics
9. Effect of troglitazone on urinary excretion of cortisol and 6-βhydroxycortisol
10. Potential interaction of troglitazone and cyclosporine
11. Troglitazone in type II diabetes mellitus
12. The dynamics of drug absorption, distribution, and elimination
13. Update: Clinically significant cytochrome P-450 drug interactions
14. High prevalence of comorbid con-ditions in type 2 diabetics (DM2): UK MediPlus
15. Clinical evaluation of the potential error in pharma-cokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma-time curve
16. A comparison of the two one-sided tests proce-dure and the power approach for assessing the equivalence of aver-age bioavailability
17. Recent advances: P450 cytochrome enzymes
18. Factors affecting the absolute bioavailability of nifedipine
19. The nifedipine-rifampin interaction
20. 12C-nifedipine
21. Intraindividual variability in nifedipine pharmacokinetics and effects in healthy subjects
22. The effects of single dose of rifampicin on the pharmacokinetics of oral nifedipine
23. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors
24. The nifedipine gastrointestinal therapeutic system (GITS): Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties